News Archives

April 10, 2023

ASH 2022: Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

The noncovalent BTK inhibitor nemtabrutinib shows promising antitumor activity and a manageable safety profile in highly relapsed/refractory patients with chronic lymphocytic leukemia CLL / SLL.

March 31, 2023

CLL Society Signs onto a Joint Letter in Support of Continuing Telehealth Coverage Beyond the Expiration of the Public Health Emergency

CLL Society believes that telehealth healthcare options should continue to be an option especially for those who are immunocompromised.

March 24, 2023

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).

March 24, 2023

ASH 2022: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Tremendous progress over the past decade has been made in managing chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

March 24, 2023

Chronic Lymphocytic Leukemia Disclosure 101: Who, When, and What to Say About Your Diagnosis, Treatment, and Prognosis

One afternoon in late March 2013, a group of former colleagues and I were making small talk at a memorial service for Steve, who had just died of a brain tumor.

March 20, 2023

CLL Society’s COVID-19 Update for the Week of March 20, 2023

CLL Society is going to lessen the number of COVID-19 Updates to monthly at this time, as all trends in numbers right now seem to be on the downward slope. If (and most likely when) another surge in case numbers occur, we will reassess the need to provide more

March 16, 2023

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome

Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.

March 16, 2023

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL / SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity

March 16, 2023

ASH 2022: Dr. Jennifer Woyach on Targeting Venetoclax-Resistant Chronic Lymphocytic Leukemia (CLL) with a PROTAC-Based BCL-2/BCL-XL Protein Degrader

A novel PROTAC-based BCL-2/BCL-XL degrader was able to cause cell death in laboratory models of venetoclax-resistant chronic lymphocytic leukemia (CLL).

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News

ASH 2022: Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

CLL Society Signs onto a Joint Letter in Support of Continuing Telehealth Coverage Beyond the Expiration of the Public Health Emergency

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

ASH 2022: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Chronic Lymphocytic Leukemia Disclosure 101: Who, When, and What to Say About Your Diagnosis, Treatment, and Prognosis

CLL Society’s COVID-19 Update for the Week of March 20, 2023

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL / SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

ASH 2022: Dr. Jennifer Woyach on Targeting Venetoclax-Resistant Chronic Lymphocytic Leukemia (CLL) with a PROTAC-Based BCL-2/BCL-XL Protein Degrader

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT